A Randomized Phase II Study of Reolysin For Patients Receiving Standard Weekly Paclitaxel Therapy as Therapy For Advanced/Metastatic Breast Cancer

Trial Profile

A Randomized Phase II Study of Reolysin For Patients Receiving Standard Weekly Paclitaxel Therapy as Therapy For Advanced/Metastatic Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs Pelareorep (Primary) ; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Dec 2017 According to an Oncolytics Biotech media release, results from this trial will be presented at the Oncolytic Virotherapy Summit.
    • 11 Oct 2017 According to an Oncolytics Biotech media release, data from this trial will be presented at the 2017 BIO Investor Forum.
    • 19 Sep 2017 According to an Oncolytics Biotech media release, survival data from the study will be presented at the at the Phacilitate Immuno-Oncology Frontiers Conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top